Telescope Innovations (TELI) Corporate presentation summary

Business overview

• Develops intelligent automation platforms to accelerate R&D, manufacturing, and commercialization in chemicals, pharmaceuticals, and critical minerals sectors.

• Focuses on reducing time and costs for lab innovation, leveraging AI, robotics, and advanced analytics.

• Addresses global demand for faster, more efficient research and development, especially in health, energy, and sustainability.

• Major R&D investments in target industries: $42B in chemicals, $145B in pharma, $2T in clean energy.

Product portfolio and innovation

• Flagship product DirectInject-LC™ enables rapid chemical process analysis and is adopted by 15 of the top 20 global pharma companies.

• Product pipeline includes multi-probe versions, ICP, MS, and self-driving lab platforms for broader applications.

• Holds patents for lithium processing, battery recycling, and pharmaceutical manufacturing processes.

• Licensing IP such as ReCRFT™ for battery-grade lithium carbonate purification, offering significant cost and efficiency savings.

Business model and partnerships

• Operates a three-pronged revenue model: contract R&D, product sales via global distribution, and IP licensing.

• Strategic partnerships with industry leaders like Pfizer, Mettler Toledo, and Standard Lithium.

• Signed a global distribution agreement with Mettler Toledo, leveraging their $3.8B sales network.

• Master collaborative research agreement with Pfizer to develop self-driving labs.